JAK-STAT Inhibitor Ruxolitinib Reverses Chemotherapy-Induced Skin Aging
Cisplatin and gemcitabine trigger a DNA damage–JAK-STAT–senescence axis in skin. Blocking it with ruxolitinib reduced aging and may boost antitumor effects.
Summary
Chemotherapy drugs like cisplatin and gemcitabine don't just fight cancer — they also accelerate skin aging as a side effect. Researchers found that DNA damage caused by these drugs activates a signaling pathway called JAK-STAT in skin cells, triggering premature cellular senescence and the release of inflammatory molecules known as SASP. In mouse models and human skin cells, chemotherapy caused measurable skin deterioration including collagen breakdown and epidermal thinning. When scientists blocked JAK-STAT signaling using ruxolitinib — an already-approved drug — skin aging markers decreased significantly. Remarkably, ruxolitinib also appeared to suppress tumor growth in the same models, suggesting it could offer a dual benefit: protecting the skin while potentially improving cancer outcomes. This points to a promising new strategy for cancer patients suffering from treatment-related skin damage.
Detailed Summary
Chemotherapy remains a cornerstone of cancer treatment, but its side effects extend well beyond nausea and fatigue. One underappreciated consequence is premature skin aging — a condition that meaningfully reduces patients' quality of life and has lacked a mechanistic explanation or targeted therapy. This study sets out to fill that gap.
Researchers from Fujian Medical University used mouse models treated with cisplatin and gemcitabine, combined with human dermal fibroblast (HDF) cell cultures and transcriptomic profiling to map the molecular pathway driving chemotherapy-induced skin aging. In treated mice, they observed hallmark aging phenotypes: increased transepidermal water loss, epidermal atrophy, collagen degradation, and elevated senescence-associated secretory phenotype (SASP) factors. In HDFs, chemotherapy suppressed cell proliferation and induced senescence, confirmed by SA-β-Gal staining and EdU proliferation assays.
RNA sequencing and biochemical analyses revealed the key mechanism: chemotherapy-induced DNA damage activates the JAK-STAT signaling pathway, which then drives fibroblast senescence and SASP production — creating a pro-inflammatory, pro-aging skin environment. This DNA damage–JAK-STAT–senescence axis is the central mechanistic finding of the study.
Critically, inhibiting JAK-STAT with ruxolitinib — an FDA-approved JAK inhibitor used in myelofibrosis and other conditions — significantly reduced skin aging phenotypes and SASP secretion in both models. In an orthotopic tumor mouse model, ruxolitinib also suppressed tumor progression, suggesting it may augment rather than interfere with antitumor effects.
The implications are significant for both oncology and aging medicine. If these findings translate to humans, ruxolitinib or similar JAK inhibitors could be co-administered during chemotherapy to protect skin integrity while potentially enhancing treatment efficacy. Limitations include the preclinical nature of the work and reliance on mouse models and cell culture. Summary is based on the abstract only.
Key Findings
- Cisplatin and gemcitabine induce premature skin aging via a DNA damage–JAK-STAT–senescence axis in mice and human cells.
- Chemotherapy drives fibroblast senescence and SASP production, measurably degrading skin collagen and epidermal structure.
- Ruxolitinib, an approved JAK inhibitor, significantly reduced chemotherapy-induced skin aging markers in vivo.
- Ruxolitinib also suppressed tumor progression in an orthotopic mouse model, suggesting a potential dual therapeutic benefit.
- JAK-STAT pathway inhibition may be a viable clinical strategy to protect skin during chemotherapy without compromising efficacy.
Methodology
The study combined in vivo mouse models treated with cisplatin and gemcitabine, human dermal fibroblast cell cultures, and RNA sequencing-based transcriptomic analysis. Senescence was confirmed via SA-β-Gal staining and EdU proliferation assays. Ruxolitinib was tested both in cell culture and in an orthotopic tumor mouse model to assess therapeutic effect.
Study Limitations
All findings are preclinical — from mouse models and cell culture — so direct translation to human patients requires validation in clinical trials. Summary is based on the abstract only; full methodology, sample sizes, and effect sizes are unavailable. The orthotopic tumor model may not fully recapitulate the complexity of human cancer biology or the diverse chemotherapy regimens used clinically.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: